BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gong K, Gong ZJ, Lu PX, Ni XL, Shen S, Liu H, Wang JW, Zhang DX, Liu HB, Suo T. PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma. Biochem Biophys Res Commun 2019;516:983-90. [PMID: 31272718 DOI: 10.1016/j.bbrc.2019.06.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu Z, Yu X, Xu L, Li Y, Zeng C. Current insight into the regulation of PD-L1 in cancer. Exp Hematol Oncol 2022;11:44. [PMID: 35907881 DOI: 10.1186/s40164-022-00297-8] [Reference Citation Analysis]
2 Mao M, Cheng Y, Yang J, Chen Y, Xu L, Zhang X, Li Z, Chen C, Ju S, Zhou J, Wang L. Multifaced roles of PLAC8 in cancer. Biomark Res 2021;9:73. [PMID: 34627411 DOI: 10.1186/s40364-021-00329-1] [Reference Citation Analysis]
3 Chung S, Revia RA, Zhang M. Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy. Nanoscale Horiz 2021;6:696-717. [PMID: 34286791 DOI: 10.1039/d1nh00179e] [Reference Citation Analysis]
4 Feng X, Xue F, He G, Ni Q, Huang S. Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL‑6/JAK/STAT3‑mediated PD‑L1 activity. Int J Mol Med 2021;48:165. [PMID: 34278452 DOI: 10.3892/ijmm.2021.4998] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Feng X, Xue F, He G, Huang S, Ni Q. Banxia Xiexin Decoction Inhibits the Expression of PD-L1 Through Multi-Target and Multi-Pathway Regulation of Major Oncogenes in Gastric Cancer. Onco Targets Ther 2021;14:3297-307. [PMID: 34040394 DOI: 10.2147/OTT.S288442] [Reference Citation Analysis]
6 Yuan Y, Adam A, Zhao C, Chen H. Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy. Cancers (Basel) 2021;13:663. [PMID: 33562324 DOI: 10.3390/cancers13040663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
7 Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther 2020;5:230. [PMID: 33028805 DOI: 10.1038/s41392-020-00324-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
8 Xue Z, Yang B, Xu Q, Zhu X, Qin G. Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma. Biochem Biophys Res Commun 2020;522:952-9. [PMID: 31810606 DOI: 10.1016/j.bbrc.2019.10.104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]